SavedAdd your journal

Journals / Cardiovascular surgery and interventions / 2021 / Cilt: 8 - Sayı: 1

Evaluation of pregnant women admitted to Dokuz Eylül University Teratogenicity Information Service due to use of medications affecting the cardiovascular system

Gamze Gökalp
Orhan Şahin
Şule Kalkan
Nil Hocaoğlu
Pages
20–27
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on these study results, it is difficult to determine safety of CVMs during pregnancy and establish a causal relationship between maternal/neonatal outcomes and CVMs exposure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the demographic characteristics, maternal and neonatal outcomes of pregnant women receiving cardiovascular medications (CVMs) during pregnancy and admitted to the Teratogenicity Information Service (TIS).
📊
Key Findings & Data:Patients and methods: In this descriptive, cross-sectional, retrospective study, a total of 47 pregnant women (mean age: 34.0±5.5 years; range, 19 to 41 years) who were admitted to the TIS of Dokuz Eylul University were included between January 2014 and December 2016.
💡
Conclusion & Impact:Based on these study results, it is difficult to determine safety of CVMs during pregnancy and establish a causal relationship between maternal/neonatal outcomes and CVMs exposure.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to evaluate the demographic characteristics, maternal and neonatal outcomes of pregnant women receiving cardiovascular medications (CVMs) during pregnancy and admitted to the Teratogenicity Information Service (TIS). Patients and methods: In this descriptive, cross-sectional, retrospective study, a total of 47 pregnant women (mean age: 34.0±5.5 years; range, 19 to 41 years) who were admitted to the TIS of Dokuz Eylul University were included between January 2014 and December 2016. Demographic characteristics, types of the CVMs, concomitant medication and/or substance use, medical and obstetric histories of cases, and maternal and neonatal outcomes were evaluated. Results: The most commonly used drugs were beta-receptor antagonists. The mean gestational age at the time of delivery was 35.9±8.2 weeks and 42 infants (89.4%) were healthy. Five pregnancies (10.6%) ended in miscarriage or elective termination. No malformation was found in healthy live newborns. Conclusion: The use of CVMs during pregnancy remains as a challenging issue, as their potential effects on the developing fetus are not fully known. Based on these study results, it is difficult to determine safety of CVMs during pregnancy and establish a causal relationship between maternal/neonatal outcomes and CVMs exposure.

🔖

Cite This Article

Gökalp, G., Şahin, O., Kalkan, Ş., Hocaoğlu, N. (2022). Evaluation of pregnant women admitted to Dokuz Eylül University Teratogenicity Information Service due to use of medications affecting the cardiovascular system. Cardiovascular surgery and interventions, Cilt: 8 - Sayı: 1, 20–27. https://ajindex.com/articles/471039

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Laopaiboon M, Lumbiganon P, Intarut N, Mori R, Ganchimeg T, Vogel JP, et al. Advanced maternal age and pregnancy outcomes: a multicountry assessment. BJOG 2014;121 Suppl 1:49-56
  2. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128-37
  3. Bateman BT, Hernandez-Diaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, et al. Statins and congenital malformations: Cohort study. BMJ 2015;350:h1035
  4. Lewis G. Saving Mothers’ Lives: The continuing benefits for maternal health from the United Kingdom (UK) Confidential Enquires into Maternal Deaths. Semin Perinatol 2012;36:19-26
  5. Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st century: Causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008;199:36.e1-5
  6. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) WHO Version for; 2016. Avaible from: https://www.who.int/ classifications/icd/icdonlineversions/en/ [Accessed: March 12, 2019] 7. Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann 2014;45:301-14
  7. Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: Estimates from a Bayesian hierarchical model. Lancet Glob Health 2018;6:e380-e389
  8. Newstead-Angel J, Gibson PS. Cardiac drug use in pregnancy: Safety, effectiveness and obstetric implications. Expert Rev Cardiovasc Ther 2009;7:1569-80
  9. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: Analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004;60:659-66
  10. Demir Ö, Arici MA, Demiral Y, Tunçok Y. Evaluation of drugs exposure in pregnancy according to different risk categories: Do FDA-based decisions lead to more curettage? Turkiye Klinikleri J Med Sci 2012;32:901-9
  11. Göker A, Kadıoğlu Duman M, Gürpınar T, Muci E, Yıldırım Y, Erköseoğlu İ, et al. Retrospective evaluation of the pregnant women consulted due to drug exposure during pregnancy. Turkiye Klinikleri J Gynecol Obst 2012;22:90-4
  12. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths: Rates, risk factors, and acceleration towards 2030. Lancet 2016;387:587-603
  13. Althabe F, Moore JL, Gibbons L, Berrueta M, Goudar SS, Chomba E, et al. Adverse maternal and perinatal outcomes in adolescent pregnancies: The Global Network's Maternal N